There are 10 papers on prostate cancer incidence in aging research: 9 observational studies in people.
10 papers study it36 more mention it11 findings
5 new papers in 30 daysSee all 46 papers on prostate cancer incidence
“Furthermore, we observed an inverse association between BA measures and prostate cancer”
- Humans9
- In silico1
Interventions
1Spermidine
no changein humans1RR 1
1 study
Spermidine
no changein humans1RR 1
Spermidine was not clearly linked with prostate cancer incidence in humans (highest vs lowest quintile of dietary intake) (RR 1.00 (95% CI 0.89-1.12), highest vs lowest quintile).
“The intake of spermidine was not associated with the incidence of prostate cancer”
Humanshighest vs lowest quintile of dietary intakemales
Frontiers in nutrition
Upstream
2Northern regions of Brazil
upin humans1+2.6% annually
1 study
Northern regions of Brazil
upin humans1+2.6% annually
Northern regions of Brazil is linked with higher prostate cancer incidence in Northern regions of Brazil (1990-2021) (+2.59% annually).
“Northern regions showed lower rates but the steepest AAPC increases (e.g., incidence: + 2.59% annually in age group 70-74)”
Humansin Northern regions of Brazil (1990-2021)males
Cancer causes & control : CCC
Age
downin humans1
1 study
Age
downin humans1
age is linked with lower prostate cancer incidence in humans (Black vs White men) (-0.116 units per 5-year age group, 95% CI = -0.183 to -0.049).
“relative PCa incidence for Black vs White men significantly decreases by 0.116 units with each successive 5-year age group (95% CI = -0.183 to -0.049)”
HumansBlack vs White menmales
JNCI cancer spectrum
Associations
8Angiotensin receptor blockers
upin humans1HR 1.14
1 study
Angiotensin receptor blockers
upin humans1HR 1.14
Angiotensin receptor blockers are associated with prostate cancer incidence in humans (Compared with RAS inhibitor non-use among antihypertensive medication users) (HR 1.14, 95% CI 1.02–1.27 versus RAS inhibitor non-use).
“ARB use showed a modest association with higher prostate cancer incidence”
HumansCompared with RAS inhibitor non-use among antihypertensive medication usersMean follow-up of 11.5 years
Cancer medicine
Prostate cancer screening
upin humans1
1 study
Prostate cancer screening
upin humans1
Prostate cancer screening is associated with prostate cancer incidence in humans (Population-based screening program; comparison with the pre-screening period) (34.7 cases/100,000 inhabitants (1988–1990) to 78 cases/100,000 (2008)).
“PCa incidence increased significantly, from 34.7 cases/100,000 inhabitants (1988–1990) to 78 cases/100,000 (2008) (p=0.001).”
HumansPopulation-based screening program; comparison with the pre-screening periodprostatemales
Frontiers in oncology
Mailed psa information and testing program
upin humans1
1 study
Mailed psa information and testing program
upin humans1
Mailed psa information and testing program is associated with prostate cancer incidence in humans (Regional trends after program implementation) (386 to 659 cases/100,000 per year).
“Yearly prostate cancer incidence in the age group 50-74 years increased from 386 (2010-2013) to 659 cases/100 000 (2016-2019).”
HumansRegional trends after program implementation2010–2013 versus 2016–2019males
The 5-year outcomes of a regional population-based PSA information and testing programme
BJU international
PSA density
upin humans1HR 1.41
1 study
PSA density
upin humans1HR 1.41
PSA density is associated with prostate cancer incidence in humans (without prostate cancer at baseline) (HR 1.41, 95% CI 1.30-1.52).
“PSA density (HR, 1.41; 95% CI, 1.30-1.52) remained consistently associated with prostate cancer risk”
Humanswithout prostate cancer at baseline20 yearsmalesn = 2,651
Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years
JAMA network open
Prostate-specific antigen
upin humans1HR 1.06
1 study
Prostate-specific antigen
upin humans1HR 1.06
Prostate-specific antigen is associated with prostate cancer incidence in humans (without prostate cancer at baseline) (HR 1.06, 95% CI 1.04-1.07).
“PSA (HR, 1.06; 95% CI, 1.04-1.07), and PSA density (HR, 1.41; 95% CI, 1.30-1.52) remained consistently associated with prostate cancer risk”
Humanswithout prostate cancer at baseline20 yearsmalesn = 2,651
Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years
JAMA network open
KDM biological age, PhenoAge and homeostatic dysregulation
downin humans1
1 study
KDM biological age, PhenoAge and homeostatic dysregulation
downin humans1
KDM biological age, PhenoAge and homeostatic dysregulation is associated with prostate cancer incidence in humans.
“Furthermore, we observed an inverse association between BA measures and prostate cancer”
HumansAssociation attenuated after removing glycated hemoglobin and serum glucose from the biological age algorithmsMedian follow-up of 10.9 years
Clinical biomarker-based biological aging and risk of cancer in the UK Biobank
British journal of cancer
More on KDM biological age, PhenoAge and homeostatic dysregulation
Psa testing
upin humans1
1 study
Psa testing
upin humans1
Psa testing is associated with prostate cancer incidence in humans after 2000.
“After 2000, changes in biopsies and incidence paralleled changes in PSA screening in men 45-84 years”
Humansafter 2000males
Cancer epidemiology
Prostate-specific antigen screening
upin humans1
1 study
Prostate-specific antigen screening
upin humans1
Prostate-specific antigen screening is associated with prostate cancer incidence in humans (Population trends in Canada) (Incidence increased 12.8% per year after screening introduction, peaking at 140.8/100 000 in 1993).
“Incidence was increasing before PSA screening occurred, but rose further after it was introduced.”
HumansPopulation trends in Canadamales
CMAJ open
Funding
1 grant since 2022Prostate Cancer Foundation